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OBJECTIVES We sought to examine the association of apolipoprotein (apo) E genotypes with baseline
plasma lipid levels and severity of coronary artery disease (CAD), as well as the response to
treatment with fluvastatin in the Lipoprotein and Coronary Atherosclerosis Study (LCAS).
BACKGROUND Apo E genotypes have been associated with plasma lipid levels and CAD. However, the
influence of apo E genotypes on the response of plasma lipids and CAD progression or
regression to statin treatment in patients with mildly to moderately elevated cholesterol
remains unknown.
METHODS Apo E genotypes were determined by polymerase chain reaction and restriction mapping.
Plasma lipids were measured at baseline and 12 weeks after therapy with fluvastatin or placebo
in 320 subjects. In 287 subjects, quantitative coronary angiography was performed at baseline
and after 2.5 years of treatment.
RESULTS Subjects with the 3/3 genotype had greater reductions in total cholesterol (20.4% vs. 15.4%,
p 5 0.01) and low density lipoprotein (LDL) cholesterol (28.8% vs. 22.7%, p 5 0.03) than
did the subjects with the 3/4 or 4/4 genotype. In contrast, subjects with the 2/3 genotype (n 5
10) had a greater increase in high density lipoprotein cholesterol (19.1%) than did the subjects
with the 3/3 genotype (4.3%, p 5 0.002) and those with the 3/4 or 4/4 genotype (7.0%, p 5
0.02). Subjects with the 3/4 or 4/4 genotype had an increased frequency of previous
angioplasty, but other measures of baseline CAD severity and baseline lipids did not differ
significantly among the genotypes, nor did CAD progression or clinical events.
CONCLUSIONS Although subjects with the e4 allele had less reduction in LDL cholesterol with fluvastatin,
they had similar benefit in terms of CAD progression. (J Am Coll Cardiol 2000;36:1572–8)
© 2000 by the American College of Cardiology
Apolipoprotein (apo) E mediates the removal of lipoprotein
remnants (chylomicron remnants and intermediate density
lipoprotein) from the circulation. The gene encoding apo E
has several variants, which are estimated to account for
;10% of the interindividual variation in total serum cho-
lesterol concentration (1). The three common alleles for apo
E, in decreasing frequency, are e3, e4 and e2, which code for
the three major isoforms: apo E3 (contains cysteine at
position 112 and arginine at position 158), apo E4 (contains
arginine at positions 112 and 158) and apo E2 (contains
cysteine at positions 112 and 158). In general, apo E2 and
apo E4 isoforms have opposing effects on plasma lipids.
Compared with the e3 allele, e4 is generally associated with
increased plasma cholesterol and low density lipoprotein
(LDL) cholesterol, and e2 is associated with decreased
plasma cholesterol and LDL cholesterol (2) and increased
plasma triglycerides (3). Apo E genotypes have also been
associated with the response of plasma lipids to lipid-
lowering therapy, but the results have been conflicting.
Although some studies report a greater cholesterol reduc-
tion in response to diet in individuals with the apo E4
isoform (4,5), others found no association (6,7). Similarly,
the association of apo E genotypes with the response of
plasma lipids to treatment with 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase inhibitors (statins)
remains unclear. Previous studies have been performed,
primarily in patients with severe hypercholesterolemia, with
conflicting results. Some studies in hyperlipidemic patients
have found that those with apo E4 had lesser and those with
apo E2 had greater reductions in LDL cholesterol in
response to statin therapy (8–11), whereas others have
reported no association between apo E genotypes and LDL
cholesterol reduction (8,12–17). Apo E genotypes have also
been associated with coronary artery disease (CAD), with
the e4 allele associated with an increased risk and the e2
allele with a decreased risk for CAD (2).
In this study, we examined the association of apo E
genotypes with plasma lipid levels and severity of CAD at
baseline, and the response of plasma lipids and coronary
atherosclerosis to treatment with fluvastatin in the Lipopro-
tein and Coronary Atherosclerosis Study (LCAS) popula-
tion. LCAS included only CAD patients with mild to
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moderate elevations of LDL cholesterol, as is typical of the
majority of patients with CAD.
METHODS
Subjects. All subjects provided written, informed consent,
and the study was approved by the Institutional Review
Board of Baylor College of Medicine. The design and
primary results of LCAS have been published previously
(18,19). In brief, men and postmenopausal women aged 35
to 75 years who had at least one coronary lesion causing 30%
to 75% diameter stenosis on coronary angiography and
LDL cholesterol of 2.97 mmol/liter to 4.91 mmol/liter
(115 mg/dL to 190 mg/dL) after 10 weeks of lipid-lowering
diet therapy were randomized to receive fluvastatin (40 mg)
or placebo. Beginning at 12 weeks after randomization,
subjects who had a mean prerandomization LDL choles-
terol level $4.14 mmol/liter (160 mg/dL) despite diet
(25% of all randomized subjects) were also given open-
label adjunctive cholestyramine therapy, up to 12 g/day,
as tolerated (mean 8 g/day). Excluded from the study
were individuals who had a myocardial infarction within
six months before randomization, a mean fasting plasma
triglyceride level .3.39 mmol/liter (300 mg/dL)
(.2.82 mmol/liter [250 mg/dL] if assigned cholestyra-
mine), diabetes mellitus requiring insulin or an oral hypo-
glycemic agent, a fasting blood glucose level .9.4 mmol/
liter (170 mg/dL), uncontrolled hypertension, previous
coronary artery bypass graft surgery (CABG), atherectomy
or coronary stenting.
Genotyping and measurement of plasma lipids. Process-
ing of samples was done by laboratory personnel who had no
knowledge of the angiographic and clinical data. Apo E
genotyping was performed by polymerase chain reaction and
restriction digestion with the HhaI enzyme, as published
(20), with the exception that polyacrylamide gel electro-
phoresis was used to separate the digestion products.
Lipid concentrations were assessed in fasting blood sam-
ples drawn at weeks 22, 0 and 12 in a laboratory certified by
the U.S. National Heart, Lung, and Blood Institute /Cen-
ters for Disease Control and Prevention Part III Program
(Medical Research Laboratories, Highland Heights, Ken-
tucky), as previously described (18). To determine the effect
of fluvastatin on plasma lipid levels, lipid assessments at 12
weeks after randomization, before initiation of cholestyra-
mine, were used for analysis.
Quantitative coronary angiography. Angiography was
performed at baseline (1 to 16 weeks before randomization)
and at final follow-up (as close to week 130 as possible),
using the Cardiovascular Angiography Analysis System.
Qualifying lesions were defined by minimal lumen diameter
(MLD) $25% of the reference lumen diameter at baseline
and MLD $0.8 mm less than the reference lumen diameter
at either baseline or follow-up. Progression of CAD was
assessed by the mean intrasubject per-lesion change in
MLD, as well as categorization of subjects as having definite
progression, definite regression or mixed angiographic
change. Definite progression was defined as one or more
qualifying lesion(s) with a decrease in MLD of $0.4 mm,
including new total occlusions, and no qualifying lesion with
an increase in MLD of $0.4 mm. Definite regression was
defined as one or more qualifying lesion(s) with an increase
in MLD of $0.4 mm, no qualifying lesion with a decrease
in MLD of $0.4 mm and no new total occlusion.
Clinical events. Clinical events were defined as percutane-
ous transluminal coronary angioplasty (PTCA), CABG,
definite or probable myocardial infarction, unstable angina
pectoris requiring hospital admission and death from any
cause.
Statistical analysis. Baseline lipid values were the average
of values at weeks 22 and 0. Because of the potentially
opposing effects of e2 and e4, subjects with the 2/4 genotype
(n 5 6) were excluded from all analyses; the remaining e4
carriers (3/4 and 4/4 genotypes) were grouped together.
None of the subjects was homozygous for the e2 allele.
Genotypes were compared with respect to baseline charac-
teristics by the chi-square test (for categorical variables),
one-way analysis of variance (for continuous variables) or
the Kruskal-Wallis test (for the per-patient numbers of
qualifying lesions and total occlusions). Analysis of variance,
with changes in lipid values (total cholesterol, LDL choles-
terol, HDL cholesterol, triglyceride) as the outcome variable
and treatment (fluvastatin, placebo) and genotype (2/3, 3/3,
3/4 1 4/4) as the factors used to determine if the impact
of treatment was different for the different genotypes. A
Bonferroni procedure was performed to identify which of
the genotype comparisons accounted for significant interac-
tion effects. Potential differences among the genotypes for
baseline MLD and change in MLD by treatment were
determined by hierarchical regression analysis. Multinomial
logistic regression analysis, with categorical angiographic
change (progression, regression, mixed) as the outcome vari-
able and treatment (fluvastatin, placebo) and genotype (2/3,
3/3, 3/4 1 4/4) as the factors used to determine whether the
impact of treatment differed among the genotypes. For other
angiographic indexes and clinical events, the Fisher exact
Abbreviations and Acronyms
apo 5 apolipoprotein
CABG 5 coronary artery bypass graft surgery
CAD 5 coronary artery disease
HDL 5 high density lipoprotein
HMG-CoA 5 3-hydroxy-3-methylglutaryl coenzyme A
LCAS 5 Lipoprotein and Coronary
Atherosclerosis Study
LDL 5 low density lipoprotein
MLD 5 minimal lumen diameter
PTCA 5 percutaneous transluminal coronary
angioplasty
VLDL 5 very low density lipoprotein
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test was used to compare genotypes stratified by treatment.
The time to first clinical event was analyzed by the log-rank
test. The MLD is reported as the mean value 6 SE; all
other continuous variables are presented as the mean
value 6 SD. All calculations were performed with Stata
(Stata Corp., College Station, Texas) or the Statistical
Analysis System (SAS Institute, Cary, North Carolina).
RESULTS
Subjects. Of the 429 subjects in LCAS, 330 had apo E
genotype data as well as baseline lipid and baseline angio-
graphic data. After exclusion of subjects with the 2/4 genotype
(n 5 6), baseline characteristics were compared in 324 subjects
(Table 1). Baseline and 12-week lipid values were available for
Table 1. Baseline Characteristics of Subjects According to Apolipoprotein E Genotypes
(n 5 324)
Apo E Genotypes
2/3
(n 5 22)
3/3
(n 5 206)
3/4 and 4/4
(n 5 96)
Age (yrs) 59.2 6 8.3 58.8 6 8.1 58.6 6 7.1
Male 19 (86.4%) 170 (82.5%) 80 (83.3%)
White 19 (86.4%) 190 (92.2%) 84 (87.5%)
Height (m) 1.73 6 0.07 1.73 6 0.08 1.74 6 0.09
Weightp(kg) 78.1 6 12.6 84.4 6 15.4 88.5 6 14.1
Body mass indexp(kg/m2) 25.9 6 3.3 28.0 6 4.4 29.3 6 4.1
Waist/hip ratio 0.90 6 0.07 0.91 6 0.07 0.92 6 0.06
History of MI 11 (50.0%) 93 (45.1%) 40 (41.7%)
History of PTCA† 6 (27.3%) 55 (26.7%) 41 (42.7%)
Diabetes mellitus† 3 (13.6%) 9 (4.4%) 1 (1.0%)
Systolic BP (mm Hg) 119.0 6 17.4 124.5 6 14.8 124.0 6 15.5
Diastolic BP (mm Hg) 75.2 6 12.3 77.6 6 9.0 76.3 6 8.6
Smoker‡ 9 (40.9%) 40 (19.4%) 17 (17.7%)
Total cholesterol (mg/dL) 210.4 6 27.8 222.2 6 28.0 219.4 6 22.8
LDL cholesterol (mg/dL) 135.0 6 24.1 145.8 6 23.8 143.9 6 20.5
HDL cholesterol (mg/dL) 42.9 6 13.4 43.8 6 11.3 43.6 6 13.4
Triglycerides (mg/dL) 162.9 6 58.8 164.7 6 65.4 160.1 6 61.8
Qualifying lesions per patient 2.8 6 2.1 2.7 6 1.8 2.8 6 2.0
Total occlusions per patient 0.4 6 0.6 0.4 6 0.7 0.4 6 0.8
One or more qualifying lesions 19 (86.4%) 181 (87.9%) 86 (89.6%)
One or more total occlusion(s) 7 (31.8%) 58 (28.2%) 24 (25.0%)
MLD (mm) (mean 6 SE) 1.559 6 0.084 1.700 6 0.028 1.605 6 0.040
*p , 0.01. †p 5 0.02. ‡p 5 0.04. Data are presented as the mean value 6 SD, except for MLD, or the number (%) of subjects.
BP 5 blood pressure; HDL 5 high density lipoprotein; LDL 5 low density lipoprotein; MI 5 myocardial infarction;
MLD 5 minimal lumen diameter; PTCA 5 percutaneous transluminal coronary angioplasty.
Table 2. Apolipoprotein E Genotypes and Response of Plasma Lipids to Treatment With Fluvastatin (n 5 320)
Placebo Fluvastatin
2/3
(n 5 12)
3/3
(n 5 103)
3/4 and 4/4
(n 5 44)
2/3
(n 5 10)
3/3
(n 5 102)
3/4 and 4/4
(n 5 49)
TC
BL 205.1 6 19.9 218.9 6 27.6 218.7 6 22.5 216.8 6 35.1 225.5 6 28.3 219.2 6 23.4
FU 205.5 6 19.0 222.6 6 28.1 219.4 6 27.0 182.3 6 33.1 179.0 6 24.5 185.0 6 26.1
%D* 0.5 6 7.0 2.3 6 11.4 0.5 6 8.5 214.8 6 15.9 220.4 6 8.0 215.4 6 9.6
LDL cholesterol
BL 131.3 6 19.6 142.2 6 24.1 143.5 6 19.3 139.3 6 29.2 149.1 6 23.4 143.4 6 21.2
FU 131.2 6 21.9 145.5 6 23.7 143.7 6 22.9 103.3 6 22.3 105.1 6 18.4 110.9 6 23.8
%D† 0.6 6 13.1 3.7 6 16.6 0.4 6 10.5 223.7 6 18.8 228.8 6 11.5 222.7 6 12.7
HDL cholesterol
BL 42.4 6 11.0 43.9 6 11.1 45.4 6 15.4 43.4 6 16.4 43.6 6 11.6 42.3 6 11.5
FU 42.4 6 9.2 44.9 6 11.9 45.4 6 12.7 49.8 6 14.9 45.3 6 12.4 44.8 6 11.1
%D† 1.5 6 11.5 2.8 6 14.6 1.8 6 12.1 19.1 6 20.0 4.3 6 11.6 7.0 6 12.3
TG
BL 156.0 6 66.4 165.7 6 74.1 149.3 6 57.0 171.1 6 50.4 163.8 6 55.9 167.6 6 63.1
FU 159.9 6 56.5 162.2 6 66.7 151.3 6 68.4 145.8 6 78.5 142.4 6 54.2 146.1 6 61.8
%D 9.5 6 33.7 3.8 6 34.1 4.2 6 32.2 214.9 6 28.8 210.9 6 27.5 212.0 6 19.1
*p 5 0.01, †p 5 0.02 for interaction between apo E genotype and fluvastatin treatment. All data are in mg/dl and are represented as the mean value 6 SD.
BL 5 baseline; FU 5 12-week follow-up; TC 5 total cholesterol; TG 5 triglycerides; %D 5 percent change; other abbreviations as in Table 1.
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320 of these subjects, and baseline and follow-up (2.5-year)
angiographic data were available for 287 subjects.
Genotypes. Each allele has a unique combination of HhaI
fragment sizes. The expected digestion products of the e3
allele were 91 base pairs (bp), 48 bp and 35 bp; those of the
e2 allele were 91 bp and 83 bp; and those of the e4 allele
were 72 bp, 48 bp, 35 bp and 19 bp. A combination of the
aforementioned electrophoretic patterns identified the ge-
notypes. In the entire study group, the distribution of apo E
genotypes was 2/4 (n 5 6), 2/3 (n 5 22), 3/3 (n 5 206), 3/4
(n 5 88) and 4/4 (n 5 8). Therefore, the allele frequencies
was 0.04 for e2, 0.79 for e3 and 0.17 for e4, similar to those
in subjects in the Framingham Offspring Study (0.08, 0.78
and 0.13, respectively) (21).
Genotypes and plasma lipids. At baseline (Table 1),
subjects in the 2/3 genotype group had slightly lower total
cholesterol and LDL cholesterol than did the subjects in the
3/3 or 3/4 and 4/4 groups, but the differences were not
statistically significant.
At 12-week follow-up (Table 2), there were significant
interactions between apo E genotypes and fluvastatin ther-
apy for the percent change in total cholesterol (p 5 0.01),
LDL cholesterol (p 5 0.02) and high density lipoprotein
(HDL) cholesterol (p 5 0.02). Among the subjects treated
with fluvastatin, those in the 3/4 and 4/4 group had
significantly smaller mean reductions in total cholesterol
(p 5 0.01) and LDL cholesterol (p 5 0.03) than did
subjects in the 3/3 group (Fig. 1). In contrast, those with the
2/3 genotype had a significantly greater mean increase in
HDL cholesterol than did those in the 3/3 group (p 5
0.002) or 3/4 and 4/4 group (p 5 0.02). Only 24.5% of the
subjects in the 3/4 and 4/4 group had a $30% reduction in
LDL cholesterol 12 weeks after treatment with fluvastatin,
as compared with 50.0% of subjects with the 2/3 genotype
and 52.0% of those with the 3/3 genotype.
Genotypes and coronary atherosclerosis. Subjects in the
3/4 and 4/4 group had a higher frequency of previous
PTCA (p 5 0.02), as compared with subjects in the 2/3 and
3/3 groups. There were no other significant differences
among the genotypes in indexes of severity of CAD at
baseline (Table 1).
Regarding apo E genotypes and progression or regression
of CAD, modest differences, albeit not statistically signifi-
cant, were noted (Table 3). Among the subjects receiving
placebo, approximately one-half of those in the 3/4 and 4/4
group had progression of CAD, in contrast to only 10% of
subjects with the 2/3 genotype. Similarly, the subjects
receiving placebo in the 3/4 and 4/4 group had a greater loss
in MLD (20.140 6 0.037) than did those with the 2/3
genotype (20.014 6 0.075).
Overall, there was no significant treatment–genotype
interaction between apo E genotype and fluvastatin therapy
with respect to progression or regression of CAD. However,
there was a tendency toward greater angiographic benefit
with fluvastatin in subjects with the 3/4 or 4/4 genotype and
less in subjects with the 2/3 genotype, as compared with
subjects with the 3/3 genotype. The treatment effect of
fluvastatin, calculated as the difference between MLD
change with fluvastatin and MLD change with placebo, was
somewhat greater in subjects in the 3/4 and 4/4 genotype
group—0.092 as compared with 0.077 in subjects in the 3/3
Table 3. Apolipoprotein E Genotypes and Response of Coronary Atherosclerosis and Clinical Events to Treatment With Fluvastatin
(n 5 287)
Placebo Fluvastatin
2/3
(n 5 10)
3/3
(n 5 92)
3/4 and 4/4
(n 5 40)
2/3
(n 5 9)
3/3
(n 5 90)
3/4 and 4/4
(n 5 46)
One or more new lesion(s) 4 (40.0%) 39 (42.4%) 12 (30.0%) 3 (33.3%) 24 (26.7%) 11 (23.9%)
One or more new total
occlusion(s)
0 5 (5.4%) 3 (7.5%) 0 4 (4.4%) 2 (4.3%)
Categorical angiographic change
Progression 1 (10.0%) 35 (38.0%) 19 (47.5%) 3 (33.3%) 26 (28.9%) 13 (28.3%)
Regression 1 (10.0%) 10 (10.9%) 2 (5.0%) 2 (22.2%) 14 (15.6%) 5 (10.9%)
Mixed change 8 (80.0%) 47 (51.1%) 19 (47.5%) 4 (44.4%) 50 (55.6%) 28 (60.9%)
DMLD (mm, mean 6 SE) 20.014 6 0.075 20.135 6 0.024 20.140 6 0.037 20.035 6 0.079 20.058 6 0.027 20.048 6 0.036
Clinical events 2 (20.0%) 15 (16.3%) 2 (5.0%) 1 (11.1%) 10 (11.1%) 6 (13.0%)
Data are presented as the number (%) of subjects or mean value 6 SE.
DMLD 5 minimal lumen diameter change.
Figure 1. Effect of apo E genotype on lipids (mean percent change 6 SD)
in response to fluvastatin treatment. At 12-week follow-up, the subjects
receiving fluvastatin in the 3/4 and 4/4 genotype group had significantly
smaller reductions in total cholesterol (TC) (p 5 0.01) and LDL
cholesterol (p 5 0.03) than did subjects in the 3/3 genotype group. For
HDL cholesterol, the subjects receiving fluvastatin in the 2/3 genotype
group had significantly greater increases than did the subjects in either the
3/3 genotype group (p 5 0.002) or the 3/4 and 4/4 genotype group (p 5
0.02). There was no significant interaction between treatment and geno-
type for changes in triglyceride (TG) levels. Solid bar 5 2/3 genotype;
open bar 5 3/3 genotype; shaded bar 5 3/4 and 4/4 genotypes.
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genotype group—but the difference was not statistically
significant.
Genotypes and clinical events. In subjects with angio-
grams that could be evaluated, clinical event rates (Table 3)
and time to first event were not significantly different among
the genotype groups. These results were similar to those in
the overall study group.
DISCUSSION
The main finding of this study is the association of apo E
genotypes with the response of plasma lipids to treatment
with fluvastatin. In the LCAS population, subjects with the
3/3 genotype had greater reductions in plasma total choles-
terol and LDL cholesterol in response to treatment with
fluvastatin than did those with the 3/4 or 4/4 genotype. In
contrast, subjects with the 2/3 genotype had a greater
increase in HDL cholesterol than did those with the 3/3
genotype and those with the 3/4 or 4/4 genotype. Angio-
graphic assessment of CAD showed a tendency toward
greater benefit with fluvastatin on CAD progression, mea-
sured by either MLD change or categorical assessment, in
subjects with the 3/4 or 4/4 genotype; however, the differ-
ences were not statistically significant. Overall, there were
no significant genotype–treatment interactions with regard
to quantitative angiographic indexes of progression or re-
gression of CAD. Thus, apo E genotypes were associated
with the response of plasma lipids to fluvastatin, but not
with progression or regression of CAD in the LCAS
population.
Apo E genotypes and lipids. LCAS is the first study to
examine the association of apo E genotypes with the
response of plasma lipids to treatment with a statin in
subjects with CAD and mildly to moderately elevated LDL
cholesterol, as is commonly seen in patients with CAD. A
similar association has been observed in some (8–10), but
was not significant in other (8,12–16) studies, which in-
cluded subjects with higher LDL cholesterol levels, often
because of familial hypercholesterolemia. The existing data
from these studies and ours suggest that subjects with the e2
allele have a greater LDL cholesterol reduction and subjects
with e4 allele have a lesser response to statin therapy. In a
meta-analysis of five studies (8–10,12,16), which included a
total of 625 subjects, those with the 2/2 or 2/3 genotype had
significantly greater and those with the 3/4 or 4/4 genotype
had significantly smaller LDL cholesterol reductions in
response to statin treatment than did those with the 3/3
genotype (10). In all except one (16) of the studies compar-
ing the effects of statin therapy on lipids among apo E
genotypes, the subjects were already following a lipid-
lowering diet at “baseline,” which may have confounded the
association between the apo E genotypes and the response
of plasma lipids to statins (10). In LCAS, there was no
observed relation between apo E genotype and response to
dietary therapy before randomization (data not shown).
A significant interaction between apo E genotypes and
response of HDL cholesterol to treatment with fluvastatin
was also observed in the LCAS population. Subjects with
the 2/3 genotype had a significantly greater increase in
HDL cholesterol levels as compared with those with the 3/3
genotype and those with the 3/4 or 4/4 genotype. This
observation is novel, but a similar trend has been reported
previously. Korhonen et al. (14) observed a 16% increase in
HDL cholesterol in subjects with the 2/3 genotype, as
compared with an 8% increase in subjects with the 3/3
genotype and a 1% decrease in subjects with the 4/4
genotype, but the difference was not statistically significant.
In LCAS, subjects on fluvastatin with the 2/3 genotype did
have slightly higher fasting triglyceride levels at baseline (as
might be expected because of the association reported
between e2 and triglyceride [3]), as well as slightly greater
reductions in triglyceride levels after 12 weeks of treatment,
although the differences were not statistically significant.
Patients with higher triglyceride levels and low HDL
cholesterol have been shown to have a greater increase in
HDL cholesterol with statin therapy (22). Low HDL
cholesterol levels were common in the subjects in LCAS
(23), as in patients with CAD in general, and mean HDL
cholesterol levels in LCAS were lower than those in most
other studies that examined apo E genotype and response to
statin therapy. Enhanced clearance of remnant particles and
a reduction in postprandial lipemia may be related to the
greater HDL cholesterol increases with statins observed in
both patients with low HDL cholesterol and individuals
with the 2/3 genotype.
The frequencies of apo E alleles in the LCAS population
were similar to those in the Framingham Offspring Study
overall (21). However, there was a higher frequency of
subjects with the e3 allele in LCAS (0.79) than in the subset
of the Framingham Offspring Study subjects with CAD
(0.73), and there was a lower frequency of subjects with the
e2 allele in LCAS (0.04) than in the Framingham Offspring
Study subjects with CAD (0.09) (21). The LCAS entry
criteria may account for the observed differences. In LCAS,
exclusion of subjects with triglyceride levels .3.39 mmol/
liter (300 mg/dL; .2.82 mmol/liter [250 mg/dL] in sub-
jects assigned cholestyramine) may account for the lower
percentage of subjects with the e2 allele, which has
been associated with hypertriglyceridemia, and the exclusion
of subjects with LDL cholesterol .4.91 mmol/liter
(190 mg/dL) may have reduced the percentage of subjects
with the e4 allele, which is associated with both hypercho-
lesterolemia (3,24) and CAD (21). The combined result of
excluding high LDL cholesterol and high triglyceride levels
may have led to the significantly increased frequency of e3,
as compared with the Framingham Offspring Study subjects
with CAD. Selection of subjects based on specific entry
criteria may also account for the lack of a significant
association between apo E genotypes and baseline plasma
lipid levels.
Apo E binds to lipids, heparan sulfate proteoglycans and
lipoprotein receptors (LDL receptor and LDL receptor–
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related protein) and modulates lipoprotein levels by influ-
encing the clearance rate, lipolytic conversion and very low
density lipoprotein (VLDL) triglyceride production (25).
Apo E genotypes have been postulated to affect plasma lipid
levels because of differences in binding of apo E isoforms to
receptors. Apo E2 has markedly decreased binding affinity
as compared with apo E3, whereas the binding affinity of
apo E3 and apo E4 has generally been found to be the same
(26), although some reports suggest that apo E4 has
increased affinity as compared with apo E3 (27,28). In
addition, apo E isoforms influence the binding of apo E to
lipoproteins, with apo E4 preferentially binding to VLDL
and apo E3 and apo E2 binding to the smaller,
phospholipid-rich HDL (29). In general, e2 has been
estimated to decrease LDL cholesterol by 12.5% and to
decrease HDL cholesterol by 3.1%, as compared with e3,
whereas individuals with e4 generally have higher concen-
trations of both LDL cholesterol and HDL cholesterol,
with estimated increases of 6.4% and 1.9%, respectively
(30). In LCAS, subjects with the e4 allele had a mean LDL
cholesterol reduction of 22.7%, with only 25% having
reductions in LDL cholesterol of $30%, whereas individ-
uals homozygous for the e3 allele had a mean LDL
cholesterol reduction of 28.8%, with 52% having reductions
in LDL cholesterol of $30%. One possible hypothesis to
explain the smaller reduction in LDL cholesterol in re-
sponse to statin therapy in subjects with the e4 allele is that
HMG-CoA reductase activity is already suppressed in these
individuals because of the rapid uptake of lipoprotein
remnants. Therefore, individuals with the e4 allele may have
a lesser response and may require a higher statin dosage to
achieve maximal benefit.
Apo E genotype and CAD. In LCAS, subjects with e4
were significantly more likely to have had PTCA before
entry into the study. Although other measures of baseline
severity of CAD were not significantly different among the
genotypes, all lesions in vessels with previous PTCA were
excluded from the analyses; therefore, baseline severity may
have been underestimated in these subjects because of the
predefined criteria for lesion analysis. In a meta-analysis of
five observational angiographic studies enrolling a total of
1,686 individuals, risk for angiographic CAD was signifi-
cantly increased (odds ratio 1.11) with e4 as compared with
e3; CAD risk tended to be lower with the e2 allele (odds
ratio 0.76) than with e3, but the difference was not
statistically significant (31). Although there were a limited
number of subjects with the e2 allele in LCAS, evidence to
support the reduced risk for CAD with the e2 allele includes
the lower frequency of the e2 allele (0.04) in LCAS than in
the Framingham Offspring Study overall (0.08) (21) and the
observation that LCAS subjects with the e2 allele had the
same severity of CAD but had increased nonlipid risk
factors for CAD (increased age, tobacco and diabetes), as
compared with other LCAS subjects. In a study of 424
subjects (110 without significant CAD; 118 with one-vessel,
96 with two-vessel and 100 with three-vessel disease), the
frequency of the e4 allele was directly associated and the
frequency of the e2 allele was inversely associated with the
number of diseased vessels (32). Although the correlation
was mediated largely through circulating levels of apo B and
apo B–containing lipoproteins, the significant association
between apo E genotype and CAD severity persisted after
controlling for these levels.
LCAS is the first trial of statin therapy to examine the
association of apo E genotype with angiographic indexes of
progression or regression of CAD. Among LCAS subjects,
CAD progression occurred to a similar extent (as measured
by mean MLD change) and at a similar frequency (as
measured by categorical assessment), regardless of apo E
genotype. Subjects with the e2 allele had little progression
of CAD, but the sample size was small and the difference
was not statistically significant. However, subjects with the
3/4 or 4/4 genotype, who, on the basis of observational
epidemiologic data, might be expected to have increased
CAD risk, had a somewhat greater treatment effect with
fluvastatin, as determined by the difference between MLD
change with placebo and MLD change with fluvastatin, as
compared with subjects with the 2/3 or 3/3 genotype, but
the difference was not statistically significant and the sample
size limits the power to assess differences in angiographic
indexes between the apo E alleles. In LCAS overall, LDL
cholesterol change was not a good predictor of MLD
change (33).
Because LCAS was an angiographic trial, it was not
designed to detect statistically significant differences in
clinical events. As would be expected, no significant differ-
ences in event rates or time to first event were detected
among the apo E genotype groups. However, in larger
studies and in pooled analyses, the e4 allele has been
associated with increased risk for CAD events. In a meta-
analysis of nine observational studies that measured clinical
events in a total of 6,355 individuals, risk for a CAD event
was significantly increased, with an odds ratio of 1.26 for
individuals with the e4 allele as compared with those with
e3 (31). In a nested case–control analysis of 619 participants
in the Multiple Risk Factor Intervention Trial (MRFIT), e4
was associated with increased risk for nonfatal myocardial
infarction, and particularly for CAD death, even after
adjustment for differences in baseline LDL cholesterol,
baseline HDL cholesterol, body mass index, smoking and
diastolic blood pressure (34). In a substudy of 966 patients
with CAD in the Scandinavian Simvastatin Survival Study
(4S), individuals with the e4 allele who received placebo had
an increased risk for death, with an odds ratio of 1.8, which
was abolished by treatment with simvastatin (35).
The completion of the Human Genome Project will
greatly accelerate efforts to understand pharmacogenetic
interactions that determine both disease course and response
to therapy. There are now substantial data that apo E
genotypes should be considered in studies of interventions
designed to reduce the risk for atherosclerosis. In LCAS,
fluvastatin therapy produced significantly greater reductions
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in total cholesterol and LDL cholesterol in subjects with
apo E genotype 3/3 than in subjects with 3/4 or 4/4, and a
significantly greater increase in HDL cholesterol in subjects
with the 2/3 genotype than in those with 3/3 or in those
with 3/4 or 4/4. Although subjects with the e4 allele had
significantly less LDL cholesterol reduction with fluva-
statin, they had similar benefit on CAD progression.
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